deferasirox NDC 70710-1277

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1277Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1277Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1277-1	70710127701	100 TABLET, FILM COATED in 1 BOTTLE (70710-1277-1)Marketed from Nov 21, 2019
70710-1277-3	70710127703	30 TABLET, FILM COATED in 1 BOTTLE (70710-1277-3)Marketed from Nov 21, 2019

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): deferasirox
Generic name (nonproprietary): deferasirox
Active ingredients: Deferasirox — 360 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211383
Marketing start: Nov 21, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 1A2 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Iron Chelating Activity (Mechanism)
Identifiers: Product ID 70710-1277_b011a8f6-9341-4dfb-a7cf-eb30cdae32d2SPL ID b011a8f6-9341-4dfb-a7cf-eb30cdae32d2SPL set ID 4af5bc9e-3e09-4dfd-8cc8-7677953c9c7cRxCUI 1607784, 1607792, 1607796UNII V8G4MOF2V9
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710127701 followed by a unit qualifier and the quantity

Package 70710-1277-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 24, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211383

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211383
Product	Strength	Form · route	Labeler	Product NDC
deferasirox	Deferasirox 90 mg/1	Tablet, Film coatedOral	Zydus Pharmaceuticals USA Inc.	70710-1275
deferasirox	Deferasirox 180 mg/1	Tablet, Film coatedOral	Zydus Pharmaceuticals USA Inc.	70710-1276
deferasirox	Deferasirox 90 mg/1	Tablet, Film coatedOral	Zydus Lifesciences Limited	70771-1471
deferasirox	Deferasirox 180 mg/1	Tablet, Film coatedOral	Zydus Lifesciences Limited	70771-1472
deferasirox	Deferasirox 360 mg/1	Tablet, Film coatedOral	Zydus Lifesciences Limited	70771-1473